$NBY
NovaBay Pharmaceuticals Inc

2018 Q1 Form 10-Q Financial Statement

#000143774918009439 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $2.947M $3.701M
YoY Change -20.37% 115.3%
Cost Of Revenue $251.0K $588.0K
YoY Change -57.31% -3.76%
Gross Profit $2.696M $3.113M
YoY Change -13.4% 180.96%
Gross Profit Margin 91.48% 84.11%
Selling, General & Admin $5.018M $6.828M
YoY Change -26.51% 41.48%
% of Gross Profit 186.13% 219.34%
Research & Development $46.00K $62.00K
YoY Change -25.81% -93.35%
% of Gross Profit 1.71% 1.99%
Depreciation & Amortization $41.00K $18.00K
YoY Change 127.78% -55.0%
% of Gross Profit 1.52% 0.58%
Operating Expenses $5.064M $6.890M
YoY Change -26.5% 19.64%
Operating Profit -$2.368M -$3.777M
YoY Change -37.3% -18.79%
Interest Expense $210.0K -$240.0K
YoY Change -187.5% -38.46%
% of Operating Profit
Other Income/Expense, Net $4.000K $2.000K
YoY Change 100.0% -104.88%
Pretax Income -$2.150M -$4.010M
YoY Change -46.38% -21.02%
Income Tax $1.000K
% Of Pretax Income
Net Earnings -$2.150M -$4.011M
YoY Change -46.4% -21.0%
Net Earnings / Revenue -72.96% -108.38%
Basic Earnings Per Share -$0.13 -$0.26
Diluted Earnings Per Share -$0.14 -$0.26
COMMON SHARES
Basic Shares Outstanding 16.41M 15.28M
Diluted Shares Outstanding 16.67M 15.28M

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.340M $7.400M
YoY Change 12.7% 417.48%
Cash & Equivalents $8.336M $7.399M
Short-Term Investments
Other Short-Term Assets $237.0K $455.0K
YoY Change -47.91% 5.81%
Inventory $479.0K $765.0K
Prepaid Expenses $1.036M
Receivables $2.230M $2.330M
Other Receivables $0.00 $0.00
Total Short-Term Assets $12.79M $11.53M
YoY Change 10.93% 152.82%
LONG-TERM ASSETS
Property, Plant & Equipment $435.0K $421.0K
YoY Change 3.33% 13.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $597.0K $730.0K
YoY Change -18.22%
Total Long-Term Assets $1.032M $1.151M
YoY Change -10.34% 211.08%
TOTAL ASSETS
Total Short-Term Assets $12.79M $11.53M
Total Long-Term Assets $1.032M $1.151M
Total Assets $13.82M $12.68M
YoY Change 9.0% 157.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $301.0K $798.0K
YoY Change -62.28% -56.15%
Accrued Expenses $2.838M $1.831M
YoY Change 55.0% -9.31%
Deferred Revenue $1.533M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.218M $4.302M
YoY Change -25.2% 6.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $198.0K $222.0K
YoY Change -10.81% -95.68%
Total Long-Term Liabilities $198.0K $222.0K
YoY Change -10.81% -97.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.218M $4.302M
Total Long-Term Liabilities $198.0K $222.0K
Total Liabilities $4.952M $8.326M
YoY Change -40.52% -31.92%
SHAREHOLDERS EQUITY
Retained Earnings -$108.4M -$107.7M
YoY Change 0.7% 12.64%
Common Stock $171.0K $153.0K
YoY Change 11.76% 200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.870M $4.360M
YoY Change
Total Liabilities & Shareholders Equity $13.82M $12.68M
YoY Change 9.0% 157.19%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$2.150M -$4.011M
YoY Change -46.4% -21.0%
Depreciation, Depletion And Amortization $41.00K $18.00K
YoY Change 127.78% -55.0%
Cash From Operating Activities -$464.0K -$2.006M
YoY Change -76.87% -59.33%
INVESTING ACTIVITIES
Capital Expenditures $2.000K $59.00K
YoY Change -96.61% 268.75%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.000K -$59.00K
YoY Change -96.61% 268.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.591M $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.603M -48.00K
YoY Change -11772.92% -101.2%
NET CHANGE
Cash From Operating Activities -464.0K -2.006M
Cash From Investing Activities -2.000K -59.00K
Cash From Financing Activities 5.603M -48.00K
Net Change In Cash 5.137M -2.113M
YoY Change -343.11% 121.26%
FREE CASH FLOW
Cash From Operating Activities -$464.0K -$2.006M
Capital Expenditures $2.000K $59.00K
Free Cash Flow -$466.0K -$2.065M
YoY Change -77.43% -58.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 nby Accrued Distributor Fees And Discounts Current
AccruedDistributorFeesAndDiscountsCurrent
CY2017Q4 nby Accrued Distributor Fees And Discounts Current
AccruedDistributorFeesAndDiscountsCurrent
185000
CY2016Q3 nby Area Of Property In Sublease Agreement
AreaOfPropertyInSubleaseAgreement
16465
CY2018Q1 nby Change In Accounts Payable And Accrued Liabilities For Property And Equipment Purchases
ChangeInAccountsPayableAndAccruedLiabilitiesForPropertyAndEquipmentPurchases
3000
CY2017Q1 nby Change In Accounts Payable And Accrued Liabilities For Property And Equipment Purchases
ChangeInAccountsPayableAndAccruedLiabilitiesForPropertyAndEquipmentPurchases
9000
CY2016Q3 nby Class Of Warrant Or Right Exercise Price Discount From Market Price
ClassOfWarrantOrRightExercisePriceDiscountFromMarketPrice
0.16
CY2016Q3 nby Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
3613284
CY2016Q4 nby Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
363523
CY2018Q1 nby Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
CY2018Q1 nby Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
CY2018Q1 nby Class Of Warrant Or Right Forfeited During Period
ClassOfWarrantOrRightForfeitedDuringPeriod
CY2018Q1 nby Class Of Warrant Or Right Forfeited During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedDuringPeriodWeightedAverageExercisePrice
CY2018Q1 nby Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
CY2018Q1 nby Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
CY2018Q1 nby Contract With Customer Liability Current Additions
ContractWithCustomerLiabilityCurrentAdditions
1587000
CY2018Q1 nby Contract With Customer Liability Current Deductions
ContractWithCustomerLiabilityCurrentDeductions
1438000
CY2018Q1 nby Contract With Customer Liability Deferred Revenue Current
ContractWithCustomerLiabilityDeferredRevenueCurrent
75
CY2018Q1 nby Contract With Customer Liability Deferred Revenue Current
ContractWithCustomerLiabilityDeferredRevenueCurrent
62000
CY2017Q4 nby Contract With Customer Liability Deferred Revenue Current
ContractWithCustomerLiabilityDeferredRevenueCurrent
75000
CY2018Q1 nby Contract With Customer Liability Deferred Revenue Current Additions
ContractWithCustomerLiabilityDeferredRevenueCurrentAdditions
CY2018Q1 nby Contract With Customer Liability Deferred Revenue Current Deductions
ContractWithCustomerLiabilityDeferredRevenueCurrentDeductions
13000
CY2018Q1 nby Contract With Customer Liability Product Contracts Current
ContractWithCustomerLiabilityProductContractsCurrent
1620000
CY2017Q4 nby Contract With Customer Liability Product Contracts Current
ContractWithCustomerLiabilityProductContractsCurrent
1458000
CY2018Q1 nby Contract With Customer Liability Product Distribution Current Additions
ContractWithCustomerLiabilityProductDistributionCurrentAdditions
1587000
CY2018Q1 nby Contract With Customer Liability Product Distribution Current Deductions
ContractWithCustomerLiabilityProductDistributionCurrentDeductions
1425000
CY2018Q1 nby Contract With Customer Rebate Liability Current
ContractWithCustomerRebateLiabilityCurrent
CY2018Q1 nby Prepaid Employees Benefits
PrepaidEmployeesBenefits
111000
CY2017Q4 nby Prepaid Employees Benefits
PrepaidEmployeesBenefits
112000
CY2017Q1 nby Effect Of Adoption Of New Accounting Standard
EffectOfAdoptionOfNewAccountingStandard
CY2018Q1 nby Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-16000
CY2017Q1 nby Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
56000
CY2012Q1 nby Minimum Common Stock Closing Bid Price Per Share
MinimumCommonStockClosingBidPricePerShare
66.50
CY2017Q4 nby Contract With Customer Rebate Liability Current
ContractWithCustomerRebateLiabilityCurrent
106000
CY2018Q1 nby Effect Of Adoption Of New Accounting Standard
EffectOfAdoptionOfNewAccountingStandard
2639000
CY2018Q1 nby Prepaid Due And Subscriptions
PrepaidDueAndSubscriptions
120000
CY2017Q4 nby Prepaid Due And Subscriptions
PrepaidDueAndSubscriptions
117000
CY2018Q1 nby Prepaid Fleet Leasing Costs
PrepaidFleetLeasingCosts
75000
CY2017Q4 nby Prepaid Fleet Leasing Costs
PrepaidFleetLeasingCosts
61000
CY2018Q1 nby Prepaid Sales Rebate
PrepaidSalesRebate
892000
CY2017Q4 nby Prepaid Sales Rebate
PrepaidSalesRebate
923000
CY2016Q1 nby Private Placement Commission Percentage
PrivatePlacementCommissionPercentage
0.06
CY2016Q2 nby Private Placement Commission Percentage
PrivatePlacementCommissionPercentage
0.06
CY2016Q3 nby Private Placement Commission Percentage
PrivatePlacementCommissionPercentage
0.06
CY2016Q4 nby Private Placement Commission Percentage
PrivatePlacementCommissionPercentage
0.06
CY2018Q1 nby Proceeds From Sale Of Stock Options And Restricted Stock Sold To Cover Taxes
ProceedsFromSaleOfStockOptionsAndRestrictedStockSoldToCoverTaxes
1000
CY2017Q1 nby Proceeds From Sale Of Stock Options And Restricted Stock Sold To Cover Taxes
ProceedsFromSaleOfStockOptionsAndRestrictedStockSoldToCoverTaxes
CY2018Q1 nby Proceeds From Stock Options And Restricted Stock Sold To Cover Taxes In Accounts Payable And Accrued Liabilities
ProceedsFromStockOptionsAndRestrictedStockSoldToCoverTaxesInAccountsPayableAndAccruedLiabilities
-1000
CY2017Q1 nby Proceeds From Stock Options And Restricted Stock Sold To Cover Taxes In Accounts Payable And Accrued Liabilities
ProceedsFromStockOptionsAndRestrictedStockSoldToCoverTaxesInAccountsPayableAndAccruedLiabilities
CY2018Q1 nby Rent Receivable
RentReceivable
125000
CY2017Q4 nby Rent Receivable
RentReceivable
86000
CY2018Q1 nby Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.60
CY2018Q1 nby Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P8Y109D
CY2018Q1 nby Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriod
1461000
CY2018Q1 nby Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriodWeightedAverageGrantDateFairValue
6.78
CY2018Q1 nby Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedWeightedAverageRemainingContractualTerm
P7Y328D
CY2018Q1 nby Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Number
ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber
1461000
CY2018Q1 nby Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice
6.78
CY2018Q1 nby Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm
P7Y328D
CY2017Q4 nby Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding
ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding
2960000
CY2018Q1 nby Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding
ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding
2433000
CY2017Q4 nby Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice
5.16
CY2018Q1 nby Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice
5.20
CY2018Q1 nby Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1072000
CY2018Q1 nby Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber
2106000
CY2018Q1 nby Share Based Compensation Expense For Stock Option Modification
ShareBasedCompensationExpenseForStockOptionModification
77000
CY2017Q1 nby Share Based Compensation Expense For Stock Option Modification
ShareBasedCompensationExpenseForStockOptionModification
CY2016Q3 nby Warrants Exercised Commission Paid
WarrantsExercisedCommissionPaid
338000
CY2016Q4 nby Warrants Exercised Commission Paid
WarrantsExercisedCommissionPaid
32000
CY2018Q1 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
4159
CY2018Q1 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
2225000
CY2017Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
3629000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
301000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
466000
CY2018Q1 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
0
CY2017Q1 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
0
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2855000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1672000
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2838
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
116000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
40000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
284000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
243000
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119285000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
113514000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
186000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1193000
CY2018Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
10000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
13000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2433
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2699
CY2018Q1 us-gaap Assets
Assets
13823000
CY2017Q4 us-gaap Assets
Assets
10079000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
12791000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
8995000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8336000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3199000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8810000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3673000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9986000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7873000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5137000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2113000
CY2011Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
33.25
CY2016Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
19.50
CY2016Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.15
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.81
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.81
CY2016Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3613284
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
363523
CY2016Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2039530
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
544000
CY2018Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
544000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17089000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15385000
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17089000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15385000
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
171000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
154000
CY2018Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk and Major Partners</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:13.25pt;margin-top:0pt;text-align:left;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> highly-rated, major financial institutions in the United States.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 13.25pt;text-align:left;text-indent:18pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:13.25pt;margin-top:0pt;text-align:left;">Deposits in these banks <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed the amount of federal insurance provided on such deposits. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it is exposed to significant credit risk due to the financial position of the financial institutions in which these deposits are held.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 13.25pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:13.25pt;margin-top:0pt;text-align:left;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> revenues were derived primarily from sales of Avenova directly to doctors through the Company&#x2019;s webstore and to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> major distribution partners.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:27.65pt;margin-top:0pt;text-align:left;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> revenues from our major distribution or collaboration partners greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> were as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Major distribution or collaboration partner</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Distributor A</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Distributor B</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Distributor C</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">*Not</div> greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13.25pt;margin-right:27.65pt;margin-top:0pt;text-align:left;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>accounts receivable from our major distribution partners greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> were as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13.25pt;margin-right:27.65pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div> <table border="0px" cellpadding="0pt" cellspacing="0pt" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin: 0pt auto 0pt 9pt; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Major distribution </div><div style="display: inline; font-weight: bold;">or collaboration </div><div style="display: inline; font-weight: bold;">partner</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31</div><div style="display: inline; font-weight: bold;">, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Distributor A</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Distributor B</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Distributor C</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Collaborator D</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">*</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">*Not</div> greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:27.65pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:13.25pt;margin-top:0pt;text-align:left;">The Company relies on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> contract sole source manufacturers to produce its finished goods. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any manufacturing facilities and intends to continue to rely on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties for the supply of finished goods. Third party manufacturers <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be able to meet the Company&#x2019;s needs with respect to timing, quantity or quality.</div></div></div></div></div>
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1533000
CY2018Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1682000
CY2018Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
CY2018Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
534000
CY2018Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
13000
CY2017Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
80000
CY2018Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
251000
CY2017Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
588000
CY2018Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
77000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
69000
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
261000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
286000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
41000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18000
CY2018Q1 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-214000
CY2017Q1 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
667000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
761000
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-214000
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
235000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-368000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-161000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
234000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1934000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
211000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-13000
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-108000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1622000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3088000
CY2018Q1 us-gaap Gross Profit
GrossProfit
2696000
CY2017Q1 us-gaap Gross Profit
GrossProfit
3113000
CY2018Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2150000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4010000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2018Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
264000
CY2017Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
CY2018Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
17000
CY2017Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-181000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
88000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-921000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2006000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2150000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-4011000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2364000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4011000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-464000
CY2011Q3 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
139520
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
4
CY2018Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
352000
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
346000
CY2018Q1 us-gaap Inventory Net
InventoryNet
479000
CY2017Q4 us-gaap Inventory Net
InventoryNet
504000
CY2018Q1 us-gaap Inventory Net
InventoryNet
479
CY2018Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
265000
CY2017Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
298000
CY2018Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
138000
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
140000
CY2018Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
97000
CY2017Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
99000
CY2018Q1 us-gaap Liabilities
Liabilities
4952000
CY2017Q4 us-gaap Liabilities
Liabilities
7485000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13823000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10079000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3218000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4979000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5603000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-48000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
5064000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
6890000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2368000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3777000
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
127000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
164000
CY2018Q1 us-gaap Other Assets Current
OtherAssetsCurrent
237000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
214000
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
597000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
613000
CY2018Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
198000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
197000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2018Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
CY2017Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
48000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1751000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1663000
CY2018Q1 us-gaap Prepaid Insurance
PrepaidInsurance
67000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
27000
CY2018Q1 us-gaap Prepaid Rent
PrepaidRent
124000
CY2017Q4 us-gaap Prepaid Rent
PrepaidRent
123000
CY2018Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:8.15pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Reclassifications</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:8.15pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:8.15pt;margin-top:0pt;text-align:left;">Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. Prior period amounts in the accompanying consolidated statements of operations and comprehensive loss have also been reclassified to conform to current period presentation. The reclassifications did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> change the net loss or loss per share.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:8.15pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:8.15pt;margin-top:0pt;text-align:left;">Additionally, prior period amounts in the accompanying consolidated statements of cash flow have also been reclassified to conform to current period presentation. The reclassifications did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> change net cash used in operating activities, net cash used in investing activities, or net cash provided by financing activities.</div></div></div></div></div>
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5591000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2016Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6600000
CY2016Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
900000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
719000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
714000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
435000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
471000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
435000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62000
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
474000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
474000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108435
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110585000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111074000
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2947000
CY2017Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3701000
CY2018Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3396000
CY2017Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3740000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
535000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.88
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2586000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1348000
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.35
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y219D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y109D
CY2018Q1 us-gaap Stock Issued1
StockIssued1
CY2017Q1 us-gaap Stock Issued1
StockIssued1
1000
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1518567
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4000
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2016Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2800000
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8871000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2594000
CY2018Q1 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
248000
CY2017Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
347000
CY2018Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1275000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:8.15pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:8.15pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:8.15pt;margin-top:0pt;text-align:left;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.</div></div></div></div></div>
CY2017Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1489000
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16670000
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15284000
CY2018Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
16406000
CY2017Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
15284000
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16406000
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15284000

Files In Submission

Name View Source Status
0001437749-18-009439-index-headers.html Edgar Link pending
0001437749-18-009439-index.html Edgar Link pending
0001437749-18-009439.txt Edgar Link pending
0001437749-18-009439-xbrl.zip Edgar Link pending
ex_113137.htm Edgar Link pending
ex_113138.htm Edgar Link pending
ex_113139.htm Edgar Link pending
ex_113140.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nby-20180331.xml Edgar Link completed
nby-20180331.xsd Edgar Link pending
nby-20180331_cal.xml Edgar Link unprocessable
nby-20180331_def.xml Edgar Link unprocessable
nby-20180331_lab.xml Edgar Link unprocessable
nby-20180331_pre.xml Edgar Link unprocessable
nby20180331_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending